Patients with advanced melanoma have few treatment options, and survival is poor. However, improved understanding of how the immune system interacts with cancer has led to the development of novel therapies. Ipilimumab is a monoclonal antibody that inhibits cytotoxic T-lymphocyte antigen–4 (CTLA-4), a key negative regulator of host T-cell responses. This article presents cases of patients receiving ipilimumab in clinical trials along with a discussion of their significance and relevance to nursing practice. The patients showed different response patterns to ipilimumab and also had various typical immune-related adverse events (irAEs), which were managed successfully. The atypical response patterns produced by ipilimumab likely reflect its mechanism of action, which requires time for the immune system to mount an effective antitumor response. Meanwhile, lesions may appear to enlarge as a consequence of enhanced T-cell infiltration, although this may not necessarily be true disease progression. Patients receiving ipilimumab may respond very differently compared to how they might react to chemotherapy. Responses can take weeks or months to develop; therefore, clinicians should not terminate treatment prematurely, providing the patient’s condition allows for continuation. Early recognition of irAEs combined with prompt management will ensure that events are more likely to resolve without serious consequences.

**At a Glance**

- Treatment of advanced melanoma with ipilimumab has demonstrated promising results with respect to one- and two-year survival.
- During ipilimumab treatment, lesions may appear to enlarge as a result of the immune system mounting an effective antitumor response with enhanced T-cell infiltration.
- Nurses should understand ipilimumab’s mechanism of action and possible response patterns and educate patients and their caregivers to prevent premature treatment withdrawal.

**Blanca Ledezma, MSN, NP, Sandra Binder, RN, MSN, BSc, and Omid Hamid, MD**

Prompt diagnosis and surgery are effective for early-stage melanoma, with almost 100% of patients with resected localized stage I or II tumors surviving to five years after diagnosis (Horner et al., 2009); however, melanoma continues to be an ongoing challenge in its advanced stages. Only 15% of patients with metastases will still be alive five years after diagnosis (Horner et al., 2009), and survival rarely exceeds 12 months (Eggermont, 2006). Since dacarbazine (also known as DTIC) was first introduced in the 1970s, survival has remained fundamentally unchanged in patients with advanced melanoma (Serrone, Zeuli, Sega, & Cognetti, 2000), underscoring an urgent need for new treatment strategies.

The arrival of cytokine- and vaccine-based immunotherapies in the early 1990s was promising, but those therapies have delivered...